Introduction
The development of reimbursable cell therapies, tissue engineered constructs and regenerative medicines pose significant technical and commercial challenges. However, increasing numbers of therapies are being approved by international regulatory bodies, with initial therapies now gaining reimbursement. To accelerate the development of promising products in the tissue engineering and regenerative medicine (TERM) field, translational research needs to underpin and drive the development process. Translational research, as we've defined it, is that which takes science from the bench by addressing specific technological challenges subsequently enabling the delivery of healthcare and economic benefits. As researchers at the forefront of this nascent industry, we have come to realise that the process of translation can be intricate, exceptionally resource consuming and vulnerable to unexpected obstacles. What follows is a compilation of 'tips and tricks' from the perspective of early career researchers (ECRs), based on our own experience and research, which facilitate translation and will improve the chances of successful product development.
Manage the research effectively
Perhaps the most important factor in the translation and development of a TERM therapy, or in any project, is its management. Without a clear and detailed research management plan, resources may be wasted and deliverables unmet. Outlined below are strategies to adopt in the day-to-day running of a translational research project.
Utilise project management principles
The success of a project is ultimately based upon diligent planning and execution rather than the results achieved; 'negative' results can be just as informative as 'positive'. Dividing projects into discrete work packages with clear milestones and deliverables enables resource allocation (Section 1.2) and helps in identifying potential bottlenecks and high risk elements for which mitigation/contingencies can be planned, for example, obtaining ethical approval for human-derived materials, or licensing for in vivo research. Likewise, key equipment may fail, therefore contingencies should be established in the form of service agreements, maintenance plans and where possible, alternative providers. Failure to plan ahead in these areas can significantly hinder or even halt progress of a project. Risk must be managed by anticipating it -risk registers have value.
Comprehensive project planning is essential for successful translation. The project plan is best represented by a Gantt chart with a realistic level of detail that can be followed by all stakeholders with a personal guideline of one deliverable per research associate per quarter.
The plan should be prepared and/or reviewed by all stakeholders to ensure all understand and believe in it. Translational research is often a high-risk activity and projects do not always progress as planned. It is therefore good discipline as part of the project plan to establish phase gates where the conditions for proceeding are clear. If unavoidable delays occur in one work package, identify other packages or, at a minimum, sections of a package, which could be brought forward. Milestones provide the opportunity to adapt and reassess the project as appropriate, and must have associated contingencies, so that if milestones are not achieved (e.g. processes are not reproducible, or outcomes predicted from in vitro data are not observed in vivo), pre-identified alternatives are investigated. In some situations, it may be necessary to terminate projects and/or work packages because they are no longer a good use of resource/effort. Where alternative directions for the research are pursued, the reasons for doing so must be strategic; the traditional academic approach of 'I did this because it was more interesting' is not acceptable in a translational setting.
Understanding project management tools as used in large companies for large projects is an important part of training, professional development and understanding the environment. It is worth noting, however, that for smaller projects in an academic setting, their full implementation can be overkill and recognising how to tailor these tools to achieve the desired outcome is equally important.
Prepare for day-to-day as well as long-term working
Effective project management should also account for the resources required for each experiment. Prior to experimentation, ensure sufficient quantities of consumables/reagents are in stock, and note which require advance preparation (e.g. thawing, sterilizing). Reserve necessary equipment and ensure their working operational status. When laboratory space, equipment and consumables are communal, it is good practice to appoint specific people to monitor stocks and set minimum threshold levels for key items. Similarly, establish procedures to ensure critical quality and safety activities are performed in line with good laboratory practice (GLP, discussed further in Section 4.2), for example, frequency of safety cabinet and incubator cleaning. Alongside this, having standard operating procedures (SOPs) with detailed methodologies helps maintain comparability between experiments and can serve as checklists, thereby maximising efficiency and eliminating errors.
Create an efficient data trail
Vast amounts of data can be produced from experimental procedures and analysis which require careful management. Whether on computers or in laboratory notebooks, do not simply name data/files by date or generic titles. This can cause difficulties in tracing specific data, potentially critical for intellectual property (IP) claims. Each experiment/analysis should receive a unique ID linking the scientist, paperwork and the electronic files containing both raw and analysed data. Electronic storage of completed notebooks is common industry practise, and where possible should be emulated in academia. Furthermore, and in addition to their requirements for IP, many publicly-funded research bodies have specific requirements for data management. Indeed, in light of the recent stimulus-triggered acquisition of pluripotency (STAP) controversy, data management is under greater scrutiny and it is likely that we may witness increased levels of internal auditing and data verification [1] .
Ensure the data are scientifically robust
Misleading 'data' can be very costly [1, 2] . Data robustness should be ensured through rigorous experimental design, appropriate use of statistical methods and familiarity with principles of key technologies.
Invest time in planning and designing experiments
Heed the words of G.J. Quarderer (Dow Chemical Co.), "Four to six weeks in the lab can save you an hour in the library" [3] . TERM experiments are expensive, can take weeks, even years, to complete, and involve complex biological systems. Yet in an effort to start collecting data, researchers sometimes rush into experimental work without due diligence and planning, often resulting in poorly designed experiments.
Systematic methods such as factorial design of experiments (DOE) are valuable tools that can be used to design statistically relevant experiments, identify key variables and enhance both process and product understanding [4] [5] [6] [7] . This places the emphasis on extensive planning and preparation prior to undertaking experimental work, and requires careful data analysis upon completion. The vast amount of useful data generated with minimal resource utilisation from a thorough DOE is far greater than the 'one factor at a time' (OFAT) approach, and likely to provide more value for TERM applications given the ability to identify relationships between factors at multiple levels. By taking the time upfront to plan, one can ensure that experiments are designed such that they are statistically valid with appropriate statistical tests employed to interrogate the data. No statistical 'ingenuity', however, can turn poor raw data into meaningful information.
Source raw materials carefully
Maintaining supply of within-specification raw materials is essential for consistent manufacture, but may prove particularly problematic for biological materials. Reliance on animal-derived biological materials should be eliminated where possible, but without adequate replacements, many processes still rely on them (e.g. foetal bovine serum, FBS).
Many constituents of FBS are undefined and even measurable elements vary between lots.
With this in mind, and where applicable, it is good practice to test multiple raw material lots in order to identify critical material attributes (CMAs) relevant to desired outcomes, evaluate inherent variability in these, and establish limits/thresholds to form the basis of raw material specifications. The CMAs help guide towards defining the critical quality attributes (CQAs) of the product -product characteristics that must be within specified limits to ensure safety, identity, purity and potency, e.g. cell marker expression or proliferative capacity [8] [9] [10] .
Subsequently, as raw material lots near depletion or expiry, tests should be performed to identify new lots that satisfy the CMA requirements, and in turn ensure the product CQAs are still met. Variation is inherent to biological materials but retaining as much control as possible over measurable factors can lead to more consistent, reproducible processes [9] .
The practice of reserving and buying specific lots applies to cell culture reagents generally, particularly those exhibiting biological variability such as Matrigel TM . For items which are manufactured by multiple suppliers, such as basal media and amino acid supplements, it is good practice to repeat-purchase from established suppliers [11] . Whilst this increases supply-chain risk, benefits arise in securing a consistently manufactured raw material and in developing long-term relationships with suppliers which may lead to discounted prices and preferential choice of stock. The selection process for supply of key reagents has to be rigorous and stringent (including due diligence of the supplier), and if it is necessary to switch suppliers, it is imperative to determine whether potential new materials generate products that meet the CQAs.
Understand the principles behind technologies
Key instruments, such as fluorescence-based systems, have become 'black-boxes', requiring minimal user intervention and are commonly managed by a core facility. 
Ensure the work has clinical relevance
Although clinical translation can seem a distant prospect from some regions of the TERM landscape, increased impact, utility and adoption of the technology can be achieved by considering its clinical relevance.
Align the research with appropriate 'clinical pull'
Direct the research towards 'clinical pull' factors (Textbox1), which can be broadly split into three categories, namely, benefit to public health, reimbursement available to recoup investment and utility for clinicians. Indeed, addressing unmet clinical needs will likely be crucial for the translational success of regenerative therapies [14, 15] . Following benefits to public health, likelihood of reimbursement will be, in part, determined by predicted savings for healthcare providers/insurers based on current lifetime costs of treatment and care. Such lifetime savings for chronic conditions are currently attractive opportunities for regenerative medicines [15] . For example, although treatments for spinal cord injury are potentially expensive, they may attract substantial reimbursement due to savings on healthcare personnel time, through increased patient autonomy. On the other hand, acellular products may warrant limited reimbursement per item, but could provide advantages in terms of manufacturing costs, logistics and a simpler regulatory pathway, favouring a commercial plan to treat large numbers of patients [7] . The counterpart to clinical pull, 'technology push', can provide new engineering tools (e.g. CRISPR [16] ) with strong IP that is attractive to investors, but without alignment to clinical pull there is little prospect of successful translation [14, [17] [18] [19] .
[Textbox 1]

Clinical pull -Value to patients, clinicians, healthcare providers/insurers and industry can be broadly quantified by assessing:
• Demand for treatments (current patients; new patients/year; treatments/patient)
• Utility for clinicians (likelihood of technology uptake in the clinic)
• Potential quality of life improvements (e.g. as assessed by quality-adjusted life years [20] [21] [22] [23] )
• Lifetime savings versus costs of current care (number of procedures; expected lifetime with condition)
•
Manufacturing costs and reimbursement per treatment (profit)
Often overlooked in terms of clinical pull is the need for enthusiasm amongst clinicians with respect to the utility of the technology, without which the product may never be adopted.
Therefore, engagement with clinicians in order to assess their needs and wants is essential.
Other benefits include feedback regarding therapeutic successes/failures, insights into the practicalities of administering therapies and clinical trial support/funding [24] . An example of this has been reported by researchers in the Moorfields Eye Hospital, with such arrangements providing competitive UK advantages [25] .
Broaden the applicability of the research: increase chances of success
Can the research serve as a platform technology applicable to other conditions? Platform technologies can enhance the translational utility of the research, providing multiple chances of a 'hit', reducing risk and conferring greater commercial value [15] . For example, drug/cell delivery systems could be developed with variants designed to administer different payloads, potentially treating a wide variety of pathologies. Indeed, companies such as Organogenesis, Athersys and Mesoblast have products which are approved for multiple indications, and this approach increases the chance of commercial viability [15] . However, resources should be focussed on a limited number of candidates at first, leaving the others in reserve.
Use predictive and relevant disease/injury models
Among the most influential statisticians of his generation [26] , George E.P. Box wisely noted "all models are wrong, but some are useful" [27] . It is important to quickly assess the suitability of the safety and efficacy assays to avoid wasting resources on models known to lack predictive value. Indeed, it is increasingly recognised that many in vitro and in vivo models lack predictive utility [28, 29] , with vast resources wasted on clinical trials that fail in spite of impressive preclinical data. With this in mind however, substantial inertia must be overcome for flawed models to be abandoned. These limitations can be addressed by employing a robust range of models to identify weaknesses early on, reducing the likelihood of failure when facing the heterogeneity of human patients [30] . In particular, many clinical trials employ patient stratification, as safety and efficacy frequently vary with patient age, sex, co-morbidity, genetics etc [31] . Preclinical testing can be similarly stratified by separately analysing multiple strains/species/cell lines, and perhaps co-morbidity models. In the coming era of personalised medicine, such data could identify the patients most likely to benefit from specific therapies, and spare those likely to be harmed.
The problems with current preclinical testing offer rich opportunities for academia and industry, as TERM therapies will require new assays [32] . There are financial and ethical gains to be made by developing new models that address the 3Rs (replacement, reduction and refinement of animal models), with the ideal being the complete replacement of animal usage [33] [34] [35] . The greatest incentive to abandon unreliable systems will be the development of methods that reliably reproduce preclinical results at clinical trial.
Understand the regulations
During the translation process, TERM researchers must address additional questions that not only satisfy basic science but also meet regulatory requirements to prime their research for translation.
Define the product
Region-specific regulatory bodies will have their own healthcare product definitions, which primarily differentiate between drug, medical device, advanced biologics or combination products [36] . chemical-secreting cells all fall within the combination product category [37] . Table 1 describes product classifications as defined by regulatory agencies within Europe and USA.
The initial step of classification can be challenging for TERM therapies. Their mode of action (MOA) cannot be defined as simply as traditional pharmaceuticals where MOA is a critical parameter used to determine assignment of classification. Particularly for combination products, establishing the primary MOA may be necessary for identifying appropriate approval pathways [38] .
Product classification will dictate which regulatory route a product follows. Class I medical devices have shorter routes to clinic with the rigor of regulation increasing with the complexity of the product [39, 40] . Further breakdown of the ATMP classification will significantly change the extent of regulation if the product meets both of the following criteria: a) 'Minimally manipulated' ATMPs undergo only non-substantial procedures such as centrifugation, cell separation and cryopreservation and b) 'homologous use' is when the ATMP is intended to perform the same function in the recipient as in the donor [41] .
Identifying the regulatory classification of the product can equip researchers with a framework of standards with which they can refer to during research, development and preclinical stages to ensure two key authorisations are obtained: firstly, achieving approval to conduct human clinical trials and secondly gaining marketing authorisation [42] (Figure 1 ).
Ensure compliance with regulatory standards
In order to meet good manufacturing practice (GMP) during later translation, there are standards that can be met at the early development stage, which will help build a robust portfolio of data to ease the transition towards clinical validation (Figure 1 ). Briefly discussed contaminants that cause bovine spongiform encephalopathy (BSE), and as a result regulatory bodies will ask for these materials to be sourced from animals that reside in countries certified to be free of BSE [45] . Non-clinical-grade cell sources or risk of infectious or genetic disease transmission may present significant hurdles for translation [42, 43] .
3. Consider the current approval status for all materials. When developing a new product all materials used to construct that product should be assessed. This includes all reagents that come into contact with the product during manufacture. For example, building a combination product including cells and a biomaterial will require full approval of both components.
4. Pre-clinical testing; develop in vitro and animal models to collect data output that is relevant from a regulatory standpoint including initial safety, efficacy, purity, dose response and mechanism of action in order to make the transition towards applying for approval as an investigational product more likely (Figure 1 ).
Identify the regulatory route to market and inform the regulators if necessary
Traditionally, once a pharmaceutical product has been classified by regulators, it will follow a particular well-trodden route to approval for market authorisation. However, as the TERM field is still nascent, established approval routes are lacking, which opens up the opportunity to work closely with regulators to develop a suitable route for the product.
The FDA approved its first tissue engineered product, Apligraf TM , in 1998. This product, containing viable human fibroblasts, was classified as a medical device and approved via the pre-market approval route for the treatment of chronic skin ulcers [46, 47] . Since then, many TERM products have emerged and may follow differing routes for approval (Table 2) Act) [48] . The latter act proposes a fast track system to enable time-constrained approval with exploratory clinical trial data that proves safety and 'probable' benefit. Extended post-market surveillance for prospective evidence gathering is allowed with subsequent adaptation to the original marketing authorisation. This overhaul has catalysed similar developments in Canada and the EU, where ''conditional approval and staggered licensing" are being considered [49] .
Due to these many variations and continuous developments of regulatory pathways, it is encouraged to reach out to regulators at early stages to gain scientific advice.
Understand the implications for manufacture
Identified by the UK's national stock take of regenerative medicine as a significant challenge [50] , the development of scalable, reproducible processes whilst retaining the product's CQAs is critical for translational, and ultimately product success. Unlike conventional biopharmaceutical production, cells form the basis of TERM products. Product (cell) quality must therefore be maintained all the way through from donor isolation to patient delivery.
Find out what's relevant and measure it
Improvement of production processes is achieved by obtaining a greater understanding of the product's functional metrics. This understanding will arise through the development of novel measurement and characterisation technologies, providing opportunities for innovation and novel technology development. The progress of non-invasive live cell imaging and its utilisation as a process analytical tool is one such example of the integration of novel technologies to improve process understanding and consistency [51] .
Improved product understanding is driven by the need to maintain quality in inherently variable processes. It is imperative therefore that relevant functional metrics are identified, measured and that the range of allowable variation (as determined by preclinical and clinical trial data) is quantified, whilst maintaining product quality for each process step and ensuring that the extent of variation remains within these tolerances [6, 7] . Furthermore, the traceability or correlation to a common reference, along with method validation, completes the verification of process metrology. This will drive the development of robust control systems to ensure the process always remains in a 'state of control'.
Consistently, consistently, consistently
In regulator Health Canada's Summary Basis of Decision for Remestemcel-L (Prochymal® -an allogeneic human mesenchymal stem cell therapy for acute Graft versus Host Disease), one word reverberated throughout: "consistently" [52] . From the document's conclusions "…the Chemistry and Manufacturing information submitted for Prochymal has demonstrated that the drug substance and drug product can be consistently manufactured to meet the approved specifications". It would be churlish of the translational researcher to ignore the fact that consistent manufacture is a prerequisite for regulatory approval. Developing consistent processes and repeatable procedures may require the adoption of chemically defined xenofree production and implementing methods aimed at identifying and reducing variation in biological source material. Investing in consistent manufacture and developing repeatable procedures can provide economic value, for example by reducing process deviation (and therefore the risk of batch failure) and increasing production capacity. It demonstrates a 'state of control' and a high degree of product understanding, improving the likelihood of regulatory approval.
It is also worth noting that whilst consistency is paramount to any TERM manufacturing process, achieving this can be extremely difficult, particularly for inherently variable bioprocesses such as autologous processes where donor material will differ from patient to patient [53] , as opposed to allogeneic processes where there is a degree of control with respect to biological starting material. Whilst it is unfeasible to eliminate variation entirely, understanding the sources of variation and identifying strategies to minimise these is critical and may result in a situation where differences in the product do not affect patient outcome [53] .
Consider scale from the outset
In the pharmaceutical/biopharmaceutical industries, efficiency and productivity typically plummet when processes are transferred from laboratory to industrial scale [54] . As part of due diligence and risk management, scalability should be considered from the outset, including an early assessment of cost of goods and supply chain risks.
To avoid technical issues associated with scale-up, small-scale models that demonstrate comparability with larger-scale systems should be adopted where possible. For example, small-scale stirred-tank bioreactor platforms are more reliable predictors of large-scale performance than traditional shake-flask models, reducing time to market and cost of goods [55] . Moreover, translational researchers should employ quality tools such as risk assessments and process maps to break down each process step to its constituent components and ensure that each process platform is scalable, and identify what process steps, if any, can be eliminated entirely or replaced with an alternative, more readily scalable step. Examples of these quality tools include FMEAs (Failure Mode and Effect Analysis), Ishikawa Diagrams and Pareto Charts [6] . The use of quality tools, for example, may identify reagents or consumables that are not suitable for scaled manufacture. As described above (Section 2.2) raw materials must be selected and sourced carefully in order to minimise variability. Where possible, alternatives to process critical components (i.e. surface-coatings, growth factors etc.) should be identified and if no alternative is available, the risk should be acknowledged and mitigated, for example, by securing future supply in the event of large-scale production.
Additionally, the relevant business processes should be mapped out and it should be determined which particular manufacturing processes will be constrained by economic and value-chain drivers. This may reveal insurmountable cost of goods arising from impracticable scaled production, allowing for alternative options to be considered. It is worth noting that the production and business processes will vary significantly depending on the final product. For example, a product such as autologous CD34+ transplantation which involves only the enrichment of a patient's cells will require a different manufacturing process to an autologous process which requires direct reprogramming and subsequent differentiation of the patient's starting material. This also has regulatory implications as discussed in Section 4.1, particularly where a product may or may not be considered to be 'minimally manipulated'.
Manage the commercial potential of the research
Clinical translation of TERM therapies depends on successful project management to develop a product that meets both clinical need and safety and regulatory requirements. Additionally, effective IP management is vital to deliver a viable product that offers an investable proposition to those involved. Technology transfer offices (TTOs) often provide expert, free advice to ECRs on whether research is protectable by IP and how it can be translated.
Protect the idea to establish commercial value
IP protection secures an idea's exclusivity and indicates value to potential investors. Deciding which aspects of an idea are suitable for IP protection, and who is the rightful owner of an invention, depends on both contributions to the conception and execution of an idea, as well as contractual agreements at individual institutions (Textbox 2). To maximise the impact of research and commercial value across several fields, ECRs should identify translational IP space, and appreciate its breadth. For example, one should consider whether the concept could be developed as a platform technology, with multiple potential applications (e.g. platforms applicable to various patient-specific autologous cells) [56] .
Researchers should also consider whether to seek protection in the UK, Europe, US or worldwide, and once protected, they can choose whether to self-develop (in-house or through academic/industrial collaborations), or to assign IP to another party. TTOs can assist with writing IP applications and often fund a bid for one year's protection, during which proof-ofconcept research and market value investigations can be undertaken. A full application may then be funded by the inventors, TTO, or other backers; however without funding, protection ends after one year, so sourcing funding for full IP protection is a crucial translational hurdle.
Academic ECRs should also consider the increasing pressure to disseminate research and offset this with the consequences of invalidating IP by revealing prior art. For collaborative research, describing information as proprietary or signing confidential disclosure agreements (CDAs) can safeguard ideas prior to IP applications.
[Textbox 2]_________________________________________________________________
Is it patentable?
To be patentable, ideas must be novel, not obvious, and useful [57] . This could include a new use for a pre-existing idea.
Who is the inventor?
The person conceiving the idea, or a novel step in the fabrication of the idea [57] . People instructed to perform experiments/research/development are not inventors; they have "reduced to practice" a novel idea. The inventor is often not the owner of the idea; the employer is usually the owner.
----------------------------------------------------------------------------------------------------------
Market the concept and develop a network
Successful project management (described in Section 1) should allow ECRs to identify, liaise and engage with appropriate bodies to develop a translational pathway. This may involve forming a 'spin out' or joint venture, which allows the inventor to retain some control over IP commercialization. Alternatively, IP can be sold or licenced to third parties through technology licencing agreements; however, the inventor's involvement usually ends here.
Building a personal network with those in relevant fields will enable both the development of one's reputation and allow for the identification of collaborators who can aid translation.
Forming collaborations with those experienced in scale up, automation or other manufacturing issues can help accelerate the transition to market. Importantly, national and international consortia facilitating translation from research concept to commercialisation through collaborations are becoming more common, providing straightforward access to a range of expertise [58, 59] .
Leverage funding
Funding will be required throughout stages of the translation process (Figure 3 ). Research councils and charities commonly fund proof-of-concept research, but have varying eligibility regarding funds for later stage commercialisation such as Phase I through Phase III trials [60] . Instead, alternative funding sources such as business angels, key opinion leaders or commercialisation seed funding schemes (Table 3) can be accessed for support. Eligibility criteria for these highly competitive schemes vary, often requiring matched funding from an industrial collaborator (which can be limited to small/medium enterprises, SMEs), but funders may offer additional support during the application process and post-award.
Preparing bids is time-consuming, so try to get early notice via automated notifications/alerts (e.g. Google alerts, mailing lists) and leverage collaborators' knowledge of funding trends and requirements to save both time and money.
Conclusion
Having strategically designed the concept with clinical relevance, manufacturing and regulatory hurdles in mind, validated the scientific worth, protected the idea, and sourced appropriate funding and collaborators, translation into a commercial product is feasible.
Although navigating through the translational landscape may seem daunting, we suggest that ECRs can increase their chances of success by tactically planning their research to address these common pitfalls early, minimising the chances of having to reiterate a design step later on in the commercialisation process.
Future perspective
Clinical and commercial failures in recent years have reinforced the need for the translation of TERM therapies. The industry is therefore entering a critical phase which can no longer rely on potential, but is expected to deliver efficacious, cost-effective products. Whilst this presents a significant challenge, the TERM industry is ideally positioned to capitalise on recent clinical success (e.g. T-cell immunotherapy) amidst a backdrop of renewed government/state investment (e.g. Cell Therapy Catapult, Centre for Commercialization of Regenerative Medicine). What imbues the greatest confidence of success, however, is the emergence of a generation of highly trained, committed, translationally-focussed ECRs.
Although faced with an uncertain regulatory/reimbursement landscape and complex scientific/technical obstacles, global recognition of the importance of translation will ensure that translational ECRs are given the appropriate authority to play a central role in the realisation of TERM therapies. We believe translational ECRs will rise to the challenge, learning from mistakes of the past, adopting best practices from closely aligned industries and developing innovative solutions to TERM-specific issues in a pre-competitive environment.
Executive summary
As translational ECRs in TERM, we have come to realise that the process of translation can be intricate, exceptionally resource consuming and prone to hidden obstacles. We have therefore compiled 'tips and tricks', based on our own experience and research that facilitate translation and will improve the chances of successful product development.
Manage the research effectively
• Utilise project management tools and divide the research into work packages with clear milestones and deliverables. Effective research management also includes dayto-day planning, mapping out the experimental process and identifying high risk areas and ways of mitigating these.
Ensure the data are scientifically robust
• Experiments in TERM are resource heavy. Take time and care in planning experiments and implement systematic methods such as Design of Experiments.
Source raw materials carefully and ensure that the principles of any technology, assay or technique are well understood to ensure maximum output of reliable and robust data.
Ensure the work has clinical relevance
• To increase chances of clinical and commercial success, research should be aligned with appropriate clinical pull, and where possible developed as platform technologies.
In addition, many current assays are unreliable, or unsuitable for testing TERM therapies, but these shortcomings provide rich opportunities for the development of new, TERM-relevant models with genuine predictive utility.
Understand the regulations
• Identify early on in the research programme the regulatory classification of the potential product to provide a framework of standards which can be referred to. Build compliance of regulatory standards into the process, and when necessary, be prepared to engage and inform the regulator.
Understand the implications for manufacture
• Relevant functional metrics, with associated tolerances, need to be identified and quantified to improve process and product understanding. The pursuit of consistency in manufacture is paramount and efforts must be made to avoid or minimise source of variation. Scalability should be considered from the outset with a focus not only on the technical challenges but also cost of goods and supply chain issues associated with scaled production. Table 3 . Examples of funding sources used to commercialise research. Funders are categorised based on who the funds are linked to, the location of funded research, the type of application process, the value of the award and the phase of the translational pathway that the award funds. 
Commercialise the research
Concept
IP Protection
